anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will enroll in the Food FARMacia program and receive groceries twice monthly for 6 months. They will also receive nutrition education and anticipatory guidance to support healthy meal preparation.
The invention provides a drug box for labeling carrier-free [<*>I] metaiodobenzylguanidine (MIBG) and a preparation method thereof. The drug box comprises a KitA part, a KitB part and a KitC part, and the KitA part, the KitB part and the KitC part are independently packaged. The KitA part comprises 1-50 microgrammes of MSnBG raw material drug freeze-dried powder and an appropriate amount of pH buffer agent freeze-dried powder for adjusting a pH value of the MSnBG raw material drug aqueous solution to 3.5-8.0. The KitB part comprises 10-1000 microgrammes of oxidizing agent freeze-dried powder. The KitC part comprises 6-600 microgrammes of reducing agent freeze-dried powder. The [<*>I] MIBG obtained by the drug box has the advantages of high labeling rate, less impurities and good stability, has a labeling rate of more than 90%, is conducive to clinical popularization use and solves the problem that the [<*>I] MIBG obtained by the prior art has a low labeling rate, more impurities and poor stability.
Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is a new form of coronaviruses that emerged in 2019 and causes Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 is highly contagious. The World Health Organization (WHO) suggests individual protection measures such as establishing necessary hygienic conditions, ensuring social isolation and keeping immune system strong against the complications that may develop due to Coronavirus. Both influenza and coronaviruses cause respiratory infections, which can lead to morbidity and mortality, especially in those who are immunocompromised or not immune to viruses (Zhu). Physical exercise has many effects on the human body, including the immune system. Moderate exercise appears to have a beneficial effect on immune function, which can protect against upper respiratory infections. Human being is a social entity by nature and social isolation can negatively affect individuals' psychology. There are many studies examining the effect of physical activity on the mental state of people. Different theories which claims the psychological improvements resulting from the increased levels of physical activity have also been proposed in the literature.Human being is a social entity by nature and social isolation can negatively affect individuals' psychology. There are many studies examining the effect of physical activity on the mental state of people. Different theories which claims the psychological improvements resulting from the increased levels of physical activity have also been proposed in the literature.Regular aerobic exercise and walking can not only improve the emotional state of the individuals, but may also affect the mental health by avoiding the negative thoughts and adapting to stress. The aim of this study is to increase the physical activity level, psychological condition and physical well-being with video-based exercises.
FIELD: medicine, virology, pharmacology, pharmacy. SUBSTANCE: invention relates to novel interferon effectors with respect to viruses inducing human herpes and papilloma. The base active component is a mixture of interferon aminocaproic acid or a mixture of interferon, aminocaproic acid and riboflavin and these mixtures are used for development of three novel medicinal forms: ointment, gel, suppository. Invention provides preparing the composition showing the prolonged effect interferon also with prolonged initial activity. An active component is effective with respect to oncogenic viruses of papillomas HPV-16 and HPV-18 being at their combined infection of cells with genital herpes virus HSV-2. This provides its use as a prophylactic agent preventing neoplastic transformation of uterine cervix epithelial cells. EFFECT: enhanced effectiveness of composition, valuable anticancer properties. 5 cl, 7 dwg
The invention relates to small molecular group water eye drops and a manufacture method thereof. Small molecular group water replaces water in the eye drops preparation process and the synthesis and preparation process of various components. In the prescription of the invention, in order to illustrate the preparation prescription of the small molecular group water, the ofloxacin eye drops is taken for an example. The prescription of the common ofloxacin eye drops comprises ofloxacin, hydrochloric acid, sodium dihydrogen phosphate, sodium chloride, butylparaben and injection water. The small molecular group water replaces the injection water and the water and volume fixing water, which are used in the preparation process of the ofloxacin, the hydrochloric acid, the sodium dihydrogen phosphate, the sodium chloride and the butylparaben and the solution preparation process. The technology comprises the following steps that: the small molecular group water is used for replacing the common laboratory water to prepare or synthesize the ofloxacin, the hydrochloric acid, the sodium dihydrogen phosphate, the sodium chloride, the butylparaben and the like in the prescription of the ofloxacin eye drops, the small molecular group water is used for preparing the hydrochloric acid solution with a certain concentration as solvent, the small molecular group water replaces the injection water and fixes the volume, and the applicable ofloxacin eye drops is prepared. Compared with the common eye drops, the eye drops can relieve eye fatigue better and has the beneficial effects of keeping mood stable and joyous, keeping attention concentrated and improving the work efficiency.
The present invention relates to gliocladin and its application, and belongs to the field of medical antibiotic technology. The gliocladin is obtained with the production strain and through conventional liquid or solid fermentation and extraction of the metabolite. The production strain is Gliocladium roseum Gr87 with preservation number of CGMCC No. 0807. The gliocladin has molecular expression of C21H16O2, and molecular weight 384. The gliocladin is used in preparing antibiotic for Shigella sonnei, tubercle mycobacillus, bacillus pyocyaneus, Shigella shigae, etc.
In schizophrenia, there is no conclusive link between psychopathology and vestibular dysfunction and we are not aware of any data that exists on the range of responses to caloric vestibular stimulation (CVS) in persons with schizophrenia. Initial data from another CVS study from our group suggests individuals with schizophrenia have greater reactivity to body temperature (37°C) CVS, as measured by the peak slow phase velocity of the resulting nystagmus (PSPV), than would be expected from individuals without schizophrenia versus healthy participants. Intriguingly, CVS at 37°C should not theoretically produce a significant vestibulocular reflex response due to the stimulus' approximation to body temperature. Hence, the primary aim of this study is to determine if individuals with schizophrenia will have greater vestibular reactivity, as measured by nystagmus PSPV, to CVS in comparison with healthy participants. The secondary aim is to assess illness awareness pre and post CVS administration in attempts to replicate our previous observation. A total of 20 patients with schizophrenia and 20 healthy control participants will be recruited. All participants will receive three conditions bilaterally: (1) body temperature (37°C) vestibular stimulation; (2) warm CVS (44°C), and (3) cold CVS (30°C).
Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
Acceptance and Commitment Therapy plus Education about HIV A master's level mental health professional will provide the 4-5 hour intervention for out-of-care PWH during a hospitalization. There are two important components to the intervention: Acceptance and Commitment Therapy (ACT) content, targeting avoidance with acceptance-based coping and active engagement in values-based living, and HIV education.
Instructions on installation and detailed use of chosen application will be provided before an upcoming oncology visit. Research staff will contact the participant and encourage a "practice" recording session. 15-30 minutes prior to the consultation, research staff will send an anonymous text message to the participants' mobile device with a reminder to record the visit. Three days after the consultation, research staff will send an anonymous text reminder message to the participants' mobile device to listen to the recording.
OBJECTIVE: To evaluate the prevalence, timing, clinical risk factors, and adverse outcomes associated with postpartum readmissions for maternal sepsis.
METHODS: We conducted a retrospective cohort study of delivery hospitalizations and 60-day postpartum readmissions for females aged 15-54 years with and without sepsis using the 2016-2020 Nationwide Readmissions Database. Temporal trends in sepsis diagnoses during delivery hospitalizations and 60-day postpartum readmissions were analyzed with the National Cancer Institute's Joinpoint Regression Program to estimate the average annual percent change with 95% CIs. Logistic regression models were fit to determine whether delivery hospitalization characteristics were associated with postpartum sepsis readmissions, and unadjusted and adjusted odds ratios with 95% CIs were reported. Adverse outcomes associated with sepsis during delivery hospitalization and readmission were described, including death, severe morbidity, a critical care composite, and renal failure.
RESULTS: Overall, 15,268,190 delivery hospitalizations and 256,216 associated 60-day readmissions were included after population weighting, of which 16,399 (1.1/1,000 delivery hospitalizations) had an associated diagnosis of sepsis at delivery, and 20,130 (1.3/1,000 delivery hospitalizations) had an associated diagnosis of sepsis with postpartum readmission. A sepsis diagnosis was present in 7.9% of all postpartum readmissions. Characteristics associated with postpartum sepsis readmission included younger age at delivery, Medicaid insurance, lowest median ZIP code income quartile, and chronic medical conditions such as obesity, pregestational diabetes, and chronic hypertension. Postpartum sepsis readmissions were associated with infection during the delivery hospitalization, including intra-amniotic infection or endometritis, wound infection, and delivery sepsis. Sepsis diagnoses were associated with 24.4% of maternal deaths at delivery and 38.4% postpartum, 2.2% cases of nontransfusion severe morbidity excluding sepsis at delivery and 13.6% postpartum, 15.6% of critical care composite diagnoses at delivery and 30.1% postpartum, and 11.1% of acute renal failure diagnoses at delivery and 36.4% postpartum.
CONCLUSION: Sepsis accounts for a significant proportion of postpartum readmissions and is a major contributor to adverse outcomes during delivery hospitalizations and postpartum readmissions.
Chelation of metals is widely used in the community to treat individuals with Autism Spectrum Disorder (ASD), with some surveys estimating that 1 in 12 children with autism have undergone chelation. This widespread use reflects the hypothesis that many cases of ASD are caused by exposure to thimerosal, an ethylmercury-based compound used previously in the US as a vaccine preservative for routine childhood immunizations. The prevalent use of chelation therapy stands in stark contrast with the lack of scientific or clinical evidence of efficacy, and creates a public health imperative for empiric data. Thus we propose a controlled trial of the effects of chelation on the core behavioral symptoms and overall functioning of children with ASD. The present investigation is a double-blind, randomized placebo-controlled study of the oral chelating agent meso-2,3-dimercaptosuccinic acid (DMSA; succimer) among 120 children, ages four to ten years, who meet criteria for ASD. Pre- and post-treatment behavioral ratings will be used to evaluate the efficacy of chelation. In addition, children will undergo comprehensive medical history, physical examination and laboratory analyses.

Our objective is to quantify differences in behavioral functioning between the chelation treatment group and the placebo control group. Analysis of mercury levels before and during the course of treatment will be used to confirm the expected DMSA-induced excretion of mercury and to identify differences among children in the extent of excretion. Our primary hypothesis is that, on average and relative to the control group, children with ASD who undergo chelation with DMSA will show greater improvements in communication and social behavior.
This is an account of an interesting case with an unusual cardiac presentation. He is a man in his 60s who presented with chest tightness to the accident and emergency unit. The initial thoughts were of acute coronary syndrome or acute aortic syndrome. The initial set of investigations was non-conclusive. His echocardiogram which was done during hospital admission showed asymmetric hypertrophy of the heart muscle. It was prudent to assess that new finding with an MRI scan. The patient presented to the hospital twice during the investigation and was treated for a lower respiratory tract infection. The MRI report showed an interventricular mass lesion extending to the right ventricular free wall with angiosarcoma being high up in the differential diagnosis. Going through the heart team discussion, the decision was to go for a transcatheter biopsy. The biopsy showed B-cell lymphoma. The treatment started and interestingly with satisfactory results.
Lateral epicondylitis (LE) is a painful situation, which usually occurs due to the overuse of the wrist extensor muscles. The prevalence of LE is 1%-3% in both men and women, and it is highest in individuals aged \>40 years. Pain and tenderness over the lateral epicondyle of the humerus at the origin of the common extensor tendon are the main characteristics. Different conservative treatment methods have been used for treating LE; however, no standard protocol has been documented in the literature. Physiotherapy programs have focused on relieving pain, controlling inflammation, and increasing muscle strength and endurance. The use of eccentric strengthening programs has been supported by current research. Eccentric exercises have been demonstrated to reduce pain and increase function in patients with LE. Recently, neuromobilization techniques have been employed in treating musculoskeletal problems and various compression syndromes. These techniques aimed to provide nerve gliding via joint movements wherein a therapist extends the nerve length in one joint while shortening the same in the adjacent joint. This tensioning technique increases the distance between each end of the nerve, and this neural elongation ability significantly decreases in patients with LE. Neuromobilization techniques have been also proposed to modulate central sensitization and peripheral pain mechanisms in musculoskeletal disorders. Given that central sensitization plays an important role in the increased nociceptive reflex and hyperalgesia in LE, inducing hypoalgesia via neuromobilization techniques may provide pain relief in the long term.
PURPOSE: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary disease (COPD) is provided to reduce the number of macrophages, eosinophils, neutrophils, and lymphocytes in bronchoalveloar lavage fluid (BALF) using a Rhus javanica Linne extract, thereby being used as an active ingredient of pharmaceutical products and health foods for preventing and treating COPD. CONSTITUTION: A pharmaceutical composition for preventing and treating COPD contains a Rhus javanica Linne extract as an active ingredient. COPD includes chronic bronchitis or pulmonary emphysema. A composition for health foods for preventing and treating COPD contains the extract as an active ingredient. A pharmaceutical composition for preventing and treating lung diseases contains the extract as an active ingredient. [Reference numerals] (AA) Total inflammatory cell in waste washing solution (×10^6); (BB) Gallnut
Meloxicam capsules are a nonsteroidal anti-inflammatory drug, available as white capsules containing 5 mg or 10 mg for oral administration. The chemical name is 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1­dioxide. The molecular weight is 351.40. Its molecular formula is C14H13N3O4S2, and it has the following chemical structure.

  


  


Meloxicam is a pale yellow powder, practically insoluble in water, slightly soluble in acetone; soluble in dimethylformamide; very slightly soluble in ethanol 96% and in methanol. Meloxicam has an apparent partition coefficient (log P) =0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2.  
  
The inactive ingredients in meloxicam include: croscarmellose sodium, lactose monohydrate, magnesium stearate, meglumine, microcrystalline cellulose, povidone and sodium lauryl sulfate. The capsule shells contain: gelatin, sodium lauryl sulfate and titanium dioxide. The capsule shell is imprinted in black edible ink which contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, potassium hydroxide and purified water.
Unlike adjuvant chemotherapy, primary (preoperative) chemotherapy will shrink tumor and allow some patients to become candidates for conservative surgery and avoid mastectomy. It also is an in vivo chemosensitivity test and the result is a predictive marker for clinical outcomes. Paclitaxel is a highly active antitumor agent that promotes microtubule assembly by binding to tubulin and inhibiting depolymerization. Paclitaxel has been shown to be an effective agent in the treatment of breast cancer. Gemcitabine is a cytosine arabinoside prodrug analog and shows response rates of 15% to 46% as a single agent with very low toxicity. The combination of gemcitabine and paclitaxel is valuable because of the different mechanisms of action of each drug and their non-overlapping toxicities. Phase II studies of paclitaxel plus gemcitabine in anthracycline-pretreated metastatic breast cancer showed good tolerance and encouraging response rates (40%-55%). Paclitaxel plus gemcitabine combination showed overall survival benefit compared to paclitaxel alone in patients with metastatic breast cancer in an interim overall survival report. A phase II study with preoperative paclitaxel and gemcitabine in stage II/III showed 18 % pCR rate at NCC (ASCO 2007 abstract #11080) In HER2 positive breast cancer, HER2 targeted therapies with trastuzumab and lapatinib have shown much improved clinical response in palliative setting. It also showed that adding trastuzumab to sequential paclitaxel and FEC chemotherapy significantly increased pCR (25% vs 66.7%) in preoperative setting for HER2 positive disease. Recently, paclitaxel, gemcitabine, and trastuzumab combination (PGH) for 6 cycles in patients with HER2 positive and node positive operable breast cancer observed a strikingly high pCR rate in both tumor and LN in an interim analysis of multicenter phase II preoperative study in Korea (28 of 47 (61%)). Lapatinib (Tykerb®), a dual tyrosine kinase inhibitor of ErbB1 and HER2 signaling pathways and it has shown to inhibit the growth of HER2 overexpressing breast cancer cells that do not respond to trastuzumab after long-term conditioning. We will examine the hypothesis that paclitaxel, gemcitabine, and lapatinib (Tykerb®) (PGT) combination could improve the pathological complete response rate of HER2 positive breast cancer when applied as a preoperative chemotherapy.
The invention discloses a traditional Chinese medicine used for treating kidney deficiency, and a preparation method thereof. The medicine is composed of three-flower tickclover herb, Chinese peony, Chinese fevervine herb, Japanese creeper stem or root, epimedium, vitis thunbergii, raspberry, sunflower stem pith, white-flowered ixora herb, medlar root, white horse excrement, panax notoginseng, ligusticum, pilose asiabell root, cherokee rose fruit, Chinese hawthorn root, Chinese dodder, kelp base, and pomegranate root. The medicine provided by the invention has the advantages of reasonable formula. According to the invention, Chinese herbal medicines such as three-flower tickclover herb, Chinese peony, Chinese fevervine herb, Japanese creeper stem or root, epimedium, vitis thunbergii, raspberry, sunflower stem pith, white-flowered ixora herb, white horse excrement, and panax notoginseng are added into the raw materials. The medicine has the functions of tranquilizing, nerve soothing, nerve relaxation, fatigue relieving, meridian dredging, pain relieving, kidney nourishing, yin nourishing, and yang improving. Also, ligusticum, cherokee rose fruit, Chinese hawthorn root, and kelp base are easy to obtain, and has the advantages of rich nutrients, low cost, and good taste.